Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ECHDC2 (ImmuneEditome ID:55268)

1. Gene summary of enriched editing regions for ECHDC2

Gene summary

Gene information	Gene symbol	ECHDC2
	Gene ID	55268
	GeneSynonyms	-
	GeneCytomap	1p32.3
	GeneType	protein-coding
	GeneDescription	enoyl-CoA hydratase domain-containing protein 2, mitochondrial\|enoyl Coenzyme A hydratase domain containing 2
	GeneModificationdate	20230517
	UniprotID	Q86YB7;F5H2K9;F5H0R2;F6RJU0;F5H408;F5H4W3;F5GWU3
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr1:52906813-52907149:-	ENST00000486170.2	ENSG00000121310.15	ECHDC2	ncRNA_exonic	AluSp,AluSx3	chr1:52906813-52907149:-.alignment
chr1:52910498-52911190:-	ENST00000460612.4	ENSG00000121310.15	ECHDC2	ncRNA_intronic	AluSx1,MIR3	chr1:52910498-52911190:-.alignment
chr1:52910498-52911190:-	ENST00000463923.4	ENSG00000121310.15	ECHDC2	ncRNA_intronic	AluSx1,MIR3	chr1:52910498-52911190:-.alignment
chr1:52910498-52911190:-	ENST00000479593.4	ENSG00000121310.15	ECHDC2	ncRNA_intronic	AluSx1,MIR3	chr1:52910498-52911190:-.alignment
chr1:52910498-52911190:-	ENST00000487851.4	ENSG00000121310.15	ECHDC2	ncRNA_intronic	AluSx1,MIR3	chr1:52910498-52911190:-.alignment
chr1:52910498-52911190:-	ENST00000487866.4	ENSG00000121310.15	ECHDC2	ncRNA_intronic	AluSx1,MIR3	chr1:52910498-52911190:-.alignment
chr1:52910498-52911190:-	ENST00000488268.4	ENSG00000121310.15	ECHDC2	ncRNA_intronic	AluSx1,MIR3	chr1:52910498-52911190:-.alignment
chr1:52910498-52911190:-	ENST00000492992.1	ENSG00000121310.15	ECHDC2	ncRNA_intronic	AluSx1,MIR3	chr1:52910498-52911190:-.alignment
chr1:52910498-52911190:-	ENST00000495920.4	ENSG00000121310.15	ECHDC2	ncRNA_intronic	AluSx1,MIR3	chr1:52910498-52911190:-.alignment
chr1:52910498-52911190:-	ENST00000543419.4	ENSG00000121310.15	ECHDC2	ncRNA_intronic	AluSx1,MIR3	chr1:52910498-52911190:-.alignment
chr1:52912227-52912999:-	ENST00000480312.5	ENSG00000121310.15	ECHDC2	ncRNA_exonic	AluSp,L1ME3B,AluJb	chr1:52912227-52912999:-.alignment
chr1:52912227-52912999:-	ENST00000487866.4	ENSG00000121310.15	ECHDC2	ncRNA_exonic	AluSp,L1ME3B,AluJb	chr1:52912227-52912999:-.alignment
chr1:52912227-52912999:-	ENST00000493896.2	ENSG00000121310.15	ECHDC2	ncRNA_exonic	AluSp,L1ME3B,AluJb	chr1:52912227-52912999:-.alignment
chr1:52916931-52918332:-	ENST00000542552.1	ENSG00000121310.15	ECHDC2	exonic	MIR3,AluJb,Tigger3b,AluSx	chr1:52916931-52918332:-.alignment

Top

2. Tumor-specific enriched editing regions for ECHDC2

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr1:52912227-52912999:-	BRCA	EER	1.2001e-10
chr1:52916931-52918332:-	BRCA	EER	4.9026e-04
ENSG00000121310.15,ECHDC2	BRCA	EAG	1.2241e-05
chr1:52912227-52912999:-	KIRC	EER	8.9323e-04
ENSG00000121310.15,ECHDC2	KIRC	EAG	7.5040e-03
ENSG00000121310.15,ECHDC2	KIRP	EAG	2.2047e-02
chr1:52912227-52912999:-	THCA	EER	3.5717e-05

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr1:52912227-52912999:-	KIRP	Path	EER	7.2719e-03	4.6158e-02	0.1564
chr1:52912227-52912999:-	LUSC	Path	EER	7.6209e-03	2.1671e-02	0.1639
chr1:52912227-52912999:-	STAD	Path	EER	3.1291e-02	3.8284e-02	0.1382

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr1:52912227-52912999:-	KIRP	EER	4.5152e-02	7.8260e-03	1.8367e+04
chr1:52912227-52912999:-	SKCM	EER	6.1206e-03	3.6414e-02	1.4409e-02
ENSG00000121310.15,ECHDC2	SKCM	EAG	4.6567e-03	4.9073e-02	1.7553e-02

Top

3. Enriched editing regions and immune related genes for ECHDC2

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr1:52912227-52912999:-

PRAD

EER

ENSG00000235245,RP11-122K13.12

-0.3568

7.0270e-11

3.4246e-19

-0.4240

EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;RBM10;SF3B4;U2AF2

T_cells_CD8

GSVA_HALLMARK_ADIPOGENESIS

chr1:52912227-52912999:-

KIRC

EER

ENSG00000144026,ZNF514

-0.4592

6.4680e-12

4.0337e-13

-0.4156

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr1:52912227-52912999:-

KIRC

EER

ENSG00000268043,NBPF12

-0.4461

3.2209e-11

1.5259e-13

-0.4224

Macrophages_M0

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr1:52912227-52912999:-

KIRC

EER

ENSG00000279382,RP11-449J21.3

-0.4399

3.6060e-11

3.3507e-15

-0.4476

NK_cells_resting

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr1:52912227-52912999:-

KIRC

EER

ENSG00000167978,SRRM2

-0.4386

6.3036e-11

6.2635e-15

-0.4436

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

Macrophages_M0

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr1:52912227-52912999:-

KIRC

EER

ENSG00000095066,HOOK2

-0.4244

1.5095e-10

1.2245e-15

-0.4539

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;U2AF2

HOOK2

T_cells_CD4_memory_activated

GSVA_HALLMARK_PANCREAS_BETA_CELLS

chr1:52912227-52912999:-

KIRC

EER

ENSG00000196440,ARMCX4

-0.4272

1.7037e-10

3.6434e-13

-0.4163

ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;TIAL1;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr1:52912227-52912999:-

KIRC

EER

ENSG00000168395,ING5

-0.4276

2.0381e-10

3.9402e-13

-0.4158

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

NK_cells_resting

GSVA_HALLMARK_GLYCOLYSIS

chr1:52912227-52912999:-

KIRC

EER

ENSG00000225855,RUSC1-AS1

-0.4295

3.1853e-10

6.3625e-13

-0.4124

EIF4A3;ELAVL1;FMR1;IGF2BP2;PTBP1;SF3B4;U2AF2

B_cells_naive

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr1:52912227-52912999:-

KIRC

EER

ENSG00000275023,MLLT6

-0.4233

3.2383e-10

3.0688e-16

-0.4624

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

Macrophages_M0

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr1:52912227-52912999:-

PRAD

EER

ENSG00000235245,RP11-122K13.12

-0.3568

7.0270e-11

3.4246e-19

-0.4240

EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;RBM10;SF3B4;U2AF2

T_cells_CD8

GSVA_HALLMARK_ADIPOGENESIS

chr1:52912227-52912999:-

KIRC

EER

ENSG00000144026,ZNF514

-0.4592

6.4680e-12

4.0337e-13

-0.4156

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr1:52912227-52912999:-

KIRC

EER

ENSG00000268043,NBPF12

-0.4461

3.2209e-11

1.5259e-13

-0.4224

Macrophages_M0

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr1:52912227-52912999:-

KIRC

EER

ENSG00000279382,RP11-449J21.3

-0.4399

3.6060e-11

3.3507e-15

-0.4476

NK_cells_resting

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr1:52912227-52912999:-

KIRC

EER

ENSG00000167978,SRRM2

-0.4386

6.3036e-11

6.2635e-15

-0.4436

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

Macrophages_M0

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr1:52912227-52912999:-

KIRC

EER

ENSG00000095066,HOOK2

-0.4244

1.5095e-10

1.2245e-15

-0.4539

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;U2AF2

HOOK2

T_cells_CD4_memory_activated

GSVA_HALLMARK_PANCREAS_BETA_CELLS

chr1:52912227-52912999:-

KIRC

EER

ENSG00000196440,ARMCX4

-0.4272

1.7037e-10

3.6434e-13

-0.4163

ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;TIAL1;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr1:52912227-52912999:-

KIRC

EER

ENSG00000168395,ING5

-0.4276

2.0381e-10

3.9402e-13

-0.4158

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

NK_cells_resting

GSVA_HALLMARK_GLYCOLYSIS

chr1:52912227-52912999:-

KIRC

EER

ENSG00000225855,RUSC1-AS1

-0.4295

3.1853e-10

6.3625e-13

-0.4124

EIF4A3;ELAVL1;FMR1;IGF2BP2;PTBP1;SF3B4;U2AF2

B_cells_naive

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr1:52912227-52912999:-

KIRC

EER

ENSG00000275023,MLLT6

-0.4233

3.2383e-10

3.0688e-16

-0.4624

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

Macrophages_M0

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr1:52912227-52912999:-

PRAD

EER

ENSG00000235245,RP11-122K13.12

-0.3568

7.0270e-11

3.4246e-19

-0.4240

EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;RBM10;SF3B4;U2AF2

T_cells_CD8

GSVA_HALLMARK_ADIPOGENESIS

chr1:52912227-52912999:-

KIRC

EER

ENSG00000144026,ZNF514

-0.4592

6.4680e-12

4.0337e-13

-0.4156

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr1:52912227-52912999:-

KIRC

EER

ENSG00000268043,NBPF12

-0.4461

3.2209e-11

1.5259e-13

-0.4224

Macrophages_M0

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr1:52912227-52912999:-

KIRC

EER

ENSG00000279382,RP11-449J21.3

-0.4399

3.6060e-11

3.3507e-15

-0.4476

NK_cells_resting

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr1:52912227-52912999:-

KIRC

EER

ENSG00000167978,SRRM2

-0.4386

6.3036e-11

6.2635e-15

-0.4436

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

Macrophages_M0

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr1:52912227-52912999:-

KIRC

EER

ENSG00000095066,HOOK2

-0.4244

1.5095e-10

1.2245e-15

-0.4539

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;U2AF2

HOOK2

T_cells_CD4_memory_activated

GSVA_HALLMARK_PANCREAS_BETA_CELLS

chr1:52912227-52912999:-

KIRC

EER

ENSG00000196440,ARMCX4

-0.4272

1.7037e-10

3.6434e-13

-0.4163

ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;TIAL1;U2AF2

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr1:52912227-52912999:-

KIRC

EER

ENSG00000168395,ING5

-0.4276

2.0381e-10

3.9402e-13

-0.4158

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

NK_cells_resting

GSVA_HALLMARK_GLYCOLYSIS

chr1:52912227-52912999:-

KIRC

EER

ENSG00000225855,RUSC1-AS1

-0.4295

3.1853e-10

6.3625e-13

-0.4124

EIF4A3;ELAVL1;FMR1;IGF2BP2;PTBP1;SF3B4;U2AF2

B_cells_naive

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr1:52912227-52912999:-

KIRC

EER

ENSG00000275023,MLLT6

-0.4233

3.2383e-10

3.0688e-16

-0.4624

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

Macrophages_M0

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results

Top

4. Enriched editing regions and immune related splicing for ECHDC2

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr1:52912227-52912999:-

ESCA

EER

ENSG00000143630.5

chr1

155288603:155289007:155289390:155289518

-0.2937

4.4295e-02

6.7659e-08

-0.4974

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;U2AF2

T_cells_gamma_delta

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000121310.15,ECHDC2

ESCA

EAG

ENSG00000143630.5

chr1

155288603:155289007:155289390:155289518

-0.3006

3.4690e-02

9.9438e-08

-0.4817

ADAR;AUH;BCCIP;BUD13;CSTF2T;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP3;ILF3;KHSRP;LARP7;LIN28B;MOV10;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;RTCB;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;U2AF1;U2AF2;UPF1;XRN2

T_cells_gamma_delta

GSVA_HALLMARK_MITOTIC_SPINDLE

chr1:52912227-52912999:-

KIRC

EER

ENSG00000077044.5

chr2

233462642:233462735:233464163:233464283

-0.3859

9.0214e-09

1.9576e-12

-0.4132

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

DGKD

T_cells_follicular_helper

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr1:52912227-52912999:-

KIRC

EER

ENSG00000108848.11

chr17

50750500:50750694:50752199:50752282

-0.3826

8.5525e-08

1.0356e-16

-0.4689

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

LUC7L3

Dendritic_cells_activated

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr1:52912227-52912999:-

KIRC

EER

ENSG00000159214.8

chr1

43991607:43992639:43993889:43993964

-0.3326

5.3965e-07

2.8804e-12

-0.4308

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;RBM10;SF3B4;U2AF2

Dendritic_cells_activated

GSVA_HALLMARK_XENOBIOTIC_METABOLISM

chr1:52912227-52912999:-

KIRC

EER

ENSG00000189171.9

chr1

153626319:153626533:153626693:153627598

-0.3242

4.4892e-06

3.1309e-14

-0.4440

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;U2AF2

S100A13

T_cells_follicular_helper

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr1:52912227-52912999:-

KIRC

EER

ENSG00000088038.13

chr19

54153180:54153840:54155308:54155680

-0.4327

2.5693e-10

6.4095e-14

-0.4290

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr1:52912227-52912999:-

KIRC

EER

ENSG00000073169.9

chr22

50200978:50201590:50206316:50206440

-0.3590

8.8879e-08

1.3898e-11

-0.4054

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

B_cells_naive

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

chr1:52912227-52912999:-

KIRC

EER

ENSG00000104613.7

chr8

19845703:19849239:19851648:19851674

-0.2869

4.4981e-06

2.6241e-11

-0.4204

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

T_cells_CD8

GSVA_HALLMARK_UV_RESPONSE_UP

chr1:52912227-52912999:-

KIRC

EER

ENSG00000085662.9

chr7

134447297:134447381:134447460:134448061

-0.3806

9.0515e-08

4.0892e-13

-0.4176

BUD13;EIF4A3;ELAVL1;FMR1;IGF2BP2;LIN28B;PTBP1;RBM10;SF3B4;TIAL1;U2AF2

T_cells_follicular_helper

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

More results

Top

5. Enriched editing regions and immune infiltration for ECHDC2

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr1:52912227-52912999:-	ACC	EER	Macrophages_M2	4.1834e-02	0.3318
ENSG00000121310.15,ECHDC2	ACC	EAG	NK_cells_activated	1.7524e-02	-0.3648
chr1:52912227-52912999:-	BLCA	EER	T_cells_CD4_memory_activated	5.5237e-05	0.3016
ENSG00000121310.15,ECHDC2	BLCA	EAG	B_cells_memory	2.7816e-02	-0.1626
chr1:52912227-52912999:-	BRCA	EER	B_cells_naive	1.1638e-04	-0.1394
chr1:52916931-52918332:-	BRCA	EER	T_cells_regulatory_(Tregs)	2.3607e-03	0.1545
ENSG00000121310.15,ECHDC2	BRCA	EAG	B_cells_naive	7.6691e-03	-0.0946
chr1:52912227-52912999:-	CESC	EER	T_cells_gamma_delta	2.2119e-03	0.2661
ENSG00000121310.15,ECHDC2	CESC	EAG	NK_cells_activated	4.1038e-02	0.1711
chr1:52912227-52912999:-	COAD	EER	B_cells_memory	6.8525e-04	0.3513
ENSG00000121310.15,ECHDC2	COAD	EAG	B_cells_memory	3.3519e-02	0.2087
chr1:52912227-52912999:-	ESCA	EER	T_cells_CD8	5.1608e-03	0.2507
chr1:52916931-52918332:-	ESCA	EER	Macrophages_M2	1.0651e-02	0.3481
ENSG00000121310.15,ECHDC2	ESCA	EAG	T_cells_gamma_delta	1.4819e-02	0.2150
chr1:52912227-52912999:-	GBM	EER	B_cells_memory	1.4042e-02	0.2844
ENSG00000121310.15,ECHDC2	HNSC	EAG	NK_cells_activated	2.4036e-02	0.2987
chr1:52912227-52912999:-	KIRC	EER	T_cells_gamma_delta	8.2950e-03	0.1575
chr1:52916931-52918332:-	KIRC	EER	Macrophages_M2	1.3972e-02	-0.1899
ENSG00000121310.15,ECHDC2	KIRC	EAG	Mast_cells_resting	2.6631e-02	-0.1309
chr1:52912227-52912999:-	KIRP	EER	NK_cells_resting	5.6341e-04	0.2525
ENSG00000121310.15,ECHDC2	KIRP	EAG	NK_cells_resting	5.4133e-03	0.2010
chr1:52912227-52912999:-	LAML	EER	T_cells_CD4_memory_activated	1.4853e-02	0.3393
ENSG00000121310.15,ECHDC2	LAML	EAG	T_cells_CD4_memory_activated	3.2863e-02	0.2909
chr1:52912227-52912999:-	LGG	EER	NK_cells_resting	1.3073e-02	-0.2747
ENSG00000121310.15,ECHDC2	LGG	EAG	Mast_cells_activated	5.4554e-04	0.3536
chr1:52912227-52912999:-	LIHC	EER	Neutrophils	5.4539e-07	0.3009
ENSG00000121310.15,ECHDC2	LIHC	EAG	Neutrophils	2.7821e-06	0.2744
ENSG00000121310.15,ECHDC2	LUAD	EAG	T_cells_CD4_memory_activated	1.1633e-03	0.1810
chr1:52912227-52912999:-	LUSC	EER	Mast_cells_activated	3.1133e-02	0.1548
ENSG00000121310.15,ECHDC2	LUSC	EAG	Mast_cells_activated	4.8392e-03	0.1951
chr1:52912227-52912999:-	MESO	EER	T_cells_gamma_delta	2.6824e-02	-0.3041
ENSG00000121310.15,ECHDC2	MESO	EAG	T_cells_gamma_delta	2.8812e-02	-0.3005
chr1:52916931-52918332:-	OV	EER	Plasma_cells	6.4581e-03	0.3840
ENSG00000121310.15,ECHDC2	OV	EAG	B_cells_memory	3.6698e-02	0.1361
chr1:52912227-52912999:-	PAAD	EER	T_cells_gamma_delta	4.1241e-02	0.1793
ENSG00000121310.15,ECHDC2	PAAD	EAG	T_cells_gamma_delta	2.6034e-02	0.1952
chr1:52912227-52912999:-	PCPG	EER	T_cells_regulatory_(Tregs)	3.9856e-02	-0.2196
ENSG00000121310.15,ECHDC2	PCPG	EAG	T_cells_regulatory_(Tregs)	3.5047e-02	-0.2154
chr1:52912227-52912999:-	PRAD	EER	Macrophages_M2	2.4216e-03	0.1500
ENSG00000121310.15,ECHDC2	PRAD	EAG	Dendritic_cells_resting	7.5734e-03	0.1309
ENSG00000121310.15,ECHDC2	READ	EAG	T_cells_gamma_delta	6.8658e-03	0.4487
chr1:52912227-52912999:-	SARC	EER	Neutrophils	5.9192e-03	0.3258
chr1:52912227-52912999:-	STAD	EER	T_cells_gamma_delta	8.3565e-04	0.2156
chr1:52916931-52918332:-	STAD	EER	Eosinophils	2.1624e-02	-0.2474
ENSG00000121310.15,ECHDC2	STAD	EAG	T_cells_gamma_delta	1.3843e-02	0.1571
chr1:52912227-52912999:-	TGCT	EER	Mast_cells_activated	2.0070e-03	0.5877
ENSG00000121310.15,ECHDC2	TGCT	EAG	Mast_cells_activated	2.0011e-03	0.5679
chr1:52912227-52912999:-	THCA	EER	B_cells_memory	4.7234e-02	-0.0944
ENSG00000121310.15,ECHDC2	THCA	EAG	B_cells_memory	6.9173e-03	-0.1274
chr1:52912227-52912999:-	THYM	EER	Neutrophils	1.0184e-02	0.3241
ENSG00000121310.15,ECHDC2	UCEC	EAG	T_cells_CD8	1.8999e-02	0.2740

Top

6. Enriched editing regions and immune gene sets for ECHDC2

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr1:52912227-52912999:-	BRCA	EER	7.5545e-11	0.2334	4.5294e-05	0.1475	1.7362e-03	0.1135	3.0809e-09	0.2130
chr1:52912227-52912999:-	STAD	EER	2.9100e-06	0.2984	3.0905e-03	0.1914	7.7412e-05	0.2538	4.4956e-05	0.2618
ENSG00000121310.15,ECHDC2	STAD	EAG	2.8888e-04	0.2297	3.2189e-02	0.1369	6.3733e-04	0.2167	4.9160e-04	0.2210

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr1:52912227-52912999:-	ACC	GSVA_HALLMARK_ANGIOGENESIS	EER	1.2556e-02	0.4012
ENSG00000121310.15,ECHDC2	ACC	GSVA_HALLMARK_ANGIOGENESIS	EAG	1.1652e-02	0.3857
ENSG00000121310.15,ECHDC2	BLCA	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	2.7109e-03	0.2204
chr1:52912227-52912999:-	BLCA	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EER	6.0459e-06	0.3364
ENSG00000121310.15,ECHDC2	BRCA	GSVA_HALLMARK_GLYCOLYSIS	EAG	4.3406e-08	0.1930
chr1:52916931-52918332:-	BRCA	GSVA_HALLMARK_UV_RESPONSE_UP	EER	1.0281e-04	0.1966
chr1:52912227-52912999:-	BRCA	GSVA_HALLMARK_GLYCOLYSIS	EER	1.4586e-16	0.2937
chr1:52912227-52912999:-	CESC	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	2.1354e-02	0.2017
ENSG00000121310.15,ECHDC2	CESC	GSVA_HALLMARK_GLYCOLYSIS	EAG	8.5289e-04	0.2759
chr1:52912227-52912999:-	CHOL	GSVA_HALLMARK_GLYCOLYSIS	EER	1.3782e-04	0.6588
ENSG00000121310.15,ECHDC2	CHOL	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	3.1445e-03	0.5294
chr1:52912227-52912999:-	COAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	2.9119e-02	-0.2301
ENSG00000121310.15,ECHDC2	ESCA	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	3.1399e-03	-0.2591
chr1:52912227-52912999:-	ESCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	8.4877e-03	-0.2364
chr1:52916931-52918332:-	ESCA	GSVA_HALLMARK_HYPOXIA	EER	7.0103e-04	0.4510
chr1:52912227-52912999:-	KIRC	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	2.1996e-10	0.3676
chr1:52916931-52918332:-	KIRC	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	3.7695e-05	0.3132
ENSG00000121310.15,ECHDC2	KIRC	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	1.2886e-08	0.3278
chr1:52912227-52912999:-	KIRP	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.9783e-04	0.2718
ENSG00000121310.15,ECHDC2	KIRP	GSVA_HALLMARK_SPERMATOGENESIS	EAG	8.3766e-03	0.1908
chr1:52912227-52912999:-	LAML	GSVA_HALLMARK_DNA_REPAIR	EER	8.3911e-03	0.3653
ENSG00000121310.15,ECHDC2	LGG	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	3.0153e-04	0.3685
chr1:52912227-52912999:-	LGG	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.0750e-02	-0.2820
chr1:52912227-52912999:-	LIHC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	1.6279e-05	-0.2605
ENSG00000121310.15,ECHDC2	LIHC	GSVA_HALLMARK_PEROXISOME	EAG	1.9477e-02	-0.1388
chr1:52912227-52912999:-	LUAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	2.3219e-05	0.2425
ENSG00000121310.15,ECHDC2	LUAD	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	1.3079e-02	0.1388
chr1:52912227-52912999:-	LUSC	GSVA_HALLMARK_ADIPOGENESIS	EER	8.7752e-05	0.2778
ENSG00000121310.15,ECHDC2	LUSC	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	5.7869e-04	0.2372
chr1:52912227-52912999:-	MESO	GSVA_HALLMARK_ANGIOGENESIS	EER	1.3385e-03	0.4293
ENSG00000121310.15,ECHDC2	MESO	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	1.1201e-03	0.4354
chr1:52912227-52912999:-	OV	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	4.3619e-05	0.2650
ENSG00000121310.15,ECHDC2	OV	GSVA_HALLMARK_DNA_REPAIR	EAG	4.0765e-05	0.2638
chr1:52912227-52912999:-	PAAD	GSVA_HALLMARK_UV_RESPONSE_UP	EER	3.0193e-03	0.2582
ENSG00000121310.15,ECHDC2	PAAD	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EAG	1.8714e-02	0.2060
ENSG00000121310.15,ECHDC2	PCPG	GSVA_HALLMARK_GLYCOLYSIS	EAG	3.1589e-02	0.2196
chr1:52912227-52912999:-	PRAD	GSVA_HALLMARK_ADIPOGENESIS	EER	5.2410e-08	0.2658
ENSG00000121310.15,ECHDC2	PRAD	GSVA_HALLMARK_ADIPOGENESIS	EAG	4.1869e-04	0.1724
ENSG00000121310.15,ECHDC2	READ	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	5.9176e-04	0.5517
chr1:52912227-52912999:-	SARC	GSVA_HALLMARK_PROTEIN_SECRETION	EER	5.8004e-05	0.4615
ENSG00000121310.15,ECHDC2	SARC	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	6.4620e-08	0.5634
ENSG00000121310.15,ECHDC2	SKCM	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	2.1019e-02	0.2443
chr1:52912227-52912999:-	SKCM	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	7.3363e-03	0.2872
chr1:52906813-52907149:-	STAD	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	1.4209e-02	0.4430
ENSG00000121310.15,ECHDC2	STAD	GSVA_HALLMARK_MTORC1_SIGNALING	EAG	1.5647e-04	0.2392
chr1:52912227-52912999:-	STAD	GSVA_HALLMARK_MTORC1_SIGNALING	EER	2.7246e-06	0.2993
chr1:52912227-52912999:-	THCA	GSVA_HALLMARK_GLYCOLYSIS	EER	1.0392e-07	0.2497
ENSG00000121310.15,ECHDC2	THCA	GSVA_HALLMARK_DNA_REPAIR	EAG	4.4155e-03	-0.1343
chr1:52912227-52912999:-	THYM	GSVA_HALLMARK_DNA_REPAIR	EER	5.4767e-03	0.3487
ENSG00000121310.15,ECHDC2	THYM	GSVA_HALLMARK_IL2_STAT5_SIGNALING	EAG	1.6016e-02	-0.2977
chr1:52912227-52912999:-	UCEC	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	3.7356e-02	-0.2588
ENSG00000121310.15,ECHDC2	UCEC	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	2.4280e-03	-0.3496

Top

7. Enriched editing regions and drugs for ECHDC2

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000121310.15,ECHDC2	BLCA	GW.441756	EAG	6.8942e-04	0.2486
chr1:52912227-52912999:-	BLCA	GW.441756	EER	3.5864e-05	0.3087
chr1:52916931-52918332:-	BRCA	AKT.inhibitor.VIII	EER	2.3915e-04	0.1864
ENSG00000121310.15,ECHDC2	BRCA	EHT.1864	EAG	1.2254e-04	0.1360
chr1:52912227-52912999:-	BRCA	A.770041	EER	7.8072e-08	-0.1937
chr1:52912227-52912999:-	CESC	AZD6482	EER	2.8386e-03	0.2598
ENSG00000121310.15,ECHDC2	CESC	Metformin	EAG	6.8363e-03	0.2252
ENSG00000121310.15,ECHDC2	CHOL	JNK.Inhibitor.VIII	EAG	6.2263e-03	0.4959
chr1:52912227-52912999:-	CHOL	JNK.Inhibitor.VIII	EER	2.7006e-04	0.6367
ENSG00000121310.15,ECHDC2	COAD	BIBW2992	EAG	4.5059e-02	-0.1970
chr1:52912227-52912999:-	COAD	Elesclomol	EER	8.2579e-03	0.2768
chr1:52916931-52918332:-	ESCA	Bryostatin.1	EER	6.7017e-05	-0.5196
chr1:52912227-52912999:-	ESCA	CEP.701	EER	8.9921e-04	-0.2957
ENSG00000121310.15,ECHDC2	ESCA	Docetaxel	EAG	3.2569e-03	-0.2582
ENSG00000121310.15,ECHDC2	GBM	JW.7.52.1	EAG	7.8281e-03	0.2866
ENSG00000121310.15,ECHDC2	HNSC	BIBW2992	EAG	1.0438e-03	-0.4230
chr1:52912227-52912999:-	KIRC	MG.132	EER	3.5589e-08	-0.3226
chr1:52916931-52918332:-	KIRC	Imatinib	EER	6.0858e-04	0.2626
ENSG00000121310.15,ECHDC2	KIRC	CI.1040	EAG	1.3182e-05	-0.2541
chr1:52912227-52912999:-	KIRP	GNF.2	EER	1.1884e-06	-0.3500
ENSG00000121310.15,ECHDC2	KIRP	Axitinib	EAG	1.1261e-02	-0.1835
ENSG00000121310.15,ECHDC2	LAML	FTI.277	EAG	1.8974e-02	0.3184
chr1:52912227-52912999:-	LAML	BMS.509744	EER	3.3549e-02	-0.2982
ENSG00000121310.15,ECHDC2	LGG	BMS.708163	EAG	9.2710e-03	-0.2699
chr1:52912227-52912999:-	LGG	Lapatinib	EER	3.4401e-02	0.2354
chr1:52912227-52912999:-	LIHC	Etoposide	EER	1.8778e-05	-0.2586
chr1:52912227-52912999:-	LUAD	AG.014699	EER	2.9487e-04	-0.2083
ENSG00000121310.15,ECHDC2	LUAD	BX.795	EAG	1.0433e-02	-0.1432
ENSG00000121310.15,ECHDC2	LUSC	ATRA	EAG	1.1165e-02	0.1761
chr1:52912227-52912999:-	LUSC	ATRA	EER	4.8017e-04	0.2484
ENSG00000121310.15,ECHDC2	MESO	CHIR.99021	EAG	2.2542e-03	-0.4107
chr1:52912227-52912999:-	MESO	CHIR.99021	EER	9.4636e-04	-0.4411
chr1:52912227-52912999:-	OV	MG.132	EER	4.2737e-07	-0.3254
chr1:52916931-52918332:-	OV	BI.D1870	EER	3.3215e-02	-0.3048
ENSG00000121310.15,ECHDC2	OV	MG.132	EAG	5.5883e-06	-0.2914
chr1:52912227-52912999:-	PAAD	Camptothecin	EER	1.8326e-02	-0.2091
ENSG00000121310.15,ECHDC2	PAAD	JNJ.26854165	EAG	1.5861e-02	-0.2112
ENSG00000121310.15,ECHDC2	PCPG	EHT.1864	EAG	3.2475e-02	0.2185
ENSG00000121310.15,ECHDC2	PRAD	BMS.754807	EAG	2.7492e-04	-0.1777
chr1:52912227-52912999:-	PRAD	BAY.61.3606	EER	1.3519e-06	0.2368
ENSG00000121310.15,ECHDC2	READ	LFM.A13	EAG	9.2091e-03	0.4339
chr1:52912227-52912999:-	SARC	AUY922	EER	4.6355e-03	-0.3346
ENSG00000121310.15,ECHDC2	SARC	AKT.inhibitor.VIII	EAG	3.8030e-03	-0.3220
ENSG00000121310.15,ECHDC2	SKCM	CI.1040	EAG	1.1644e-02	-0.2663
chr1:52912227-52912999:-	SKCM	CI.1040	EER	5.3140e-03	-0.2981
ENSG00000121310.15,ECHDC2	STAD	CCT018159	EAG	7.7325e-04	-0.2134
chr1:52912227-52912999:-	STAD	Cisplatin	EER	8.3337e-05	-0.2528
chr1:52916931-52918332:-	STAD	Lenalidomide	EER	2.5718e-02	-0.2405
ENSG00000121310.15,ECHDC2	TGCT	Elesclomol	EAG	7.1975e-03	-0.5052
chr1:52912227-52912999:-	TGCT	AZD.2281	EER	5.8096e-03	-0.5354
chr1:52912227-52912999:-	THCA	CCT007093	EER	4.2510e-11	0.3070
ENSG00000121310.15,ECHDC2	THCA	GSK.650394	EAG	9.1133e-04	0.1562
chr1:52912227-52912999:-	THYM	Metformin	EER	1.5214e-03	-0.3942
ENSG00000121310.15,ECHDC2	THYM	Metformin	EAG	1.8815e-02	-0.2907
chr1:52912227-52912999:-	UCEC	Bortezomib	EER	2.3654e-02	-0.2804
ENSG00000121310.15,ECHDC2	UCEC	Dasatinib	EAG	1.3555e-03	-0.3681

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType